Analyst Consensus ?
ConsensusHold25 ratings
Bullish1248.0%
Neutral1248.0%
Bearish14.0%
Ameren Corporation · AEE · FY2025 Q2 · Calendar Q3 2025
Ameren pairs an earnings beat with data-center growth and heavy investment
The quarter supports a constructive but conditional view: management described an earnings beat, maintained guidance, and highlighted data-center demand and infrastructure investment. The case still depends on regulatory approvals, equipment availability, and execution across a large capital program.
Reported After market closeNYSEUtilities
$27.58B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.01
Consensus $0.99
EPS surprise
+2.3%
Reported versus consensus
Reported revenue
$2.22B
Consensus $1.78B
Revenue surprise
+24.7%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+1.0%
Event window
SPY move
-1.6%
Same window
Abnormal move
+2.6%
Stock minus SPY
Volume
1.5×
Versus trailing sessions
Subsequent drift
-2.3%
Up to 20 sessions
AEESPY benchmark
Ask FN2 about AEE FY2025 Q2
Transcript, numbers and history already loaded
Why did AEE rise 1.0% after beating EPS estimates in FY2025 Q2?What changed in AEE's guidance and outlook in FY2025 Q2?Give me the bull and bear case for AEE after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management highlighted a $63 billion investment pipeline, $2 billion of Q2 infrastructure investment, 2.3 GW of signed data-center construction agreements, and the planned Big Hollow Energy Center. The key change versus the prior analysis is greater emphasis on project delivery and regulatory milestones, while guidance sentiment remained maintained.
Guidance delta
Management maintained FY2025 EPS guidance of $4.85-$5.05.
Key takeaways
- Q2 EPS was described as an earnings beat, with FY2025 guidance maintained.
- Data-center demand remains a major growth driver, including 2.3 GW of signed construction agreements.
- Capital spending is increasing, with $2 billion invested in Q2 and a long-term $63 billion investment pipeline.
- Execution hinges on Missouri and Illinois regulatory milestones, MISO approvals, and generation-project delivery.
Management priorities
- Pursue Missouri large-load rate approval and related service agreements.
- Advance Big Hollow Energy Center, battery, solar, and other planned generation projects.
- Submit bids for MISO tranche 2.1 transmission projects.
- Continue infrastructure investment and pursue renewable-project tax-credit benefits.
Follow AEE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$99.64Current
$80Low
$108.31Average
$131High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 2, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Outperform | Outperform | Maintain | Sep 30, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Sep 25, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Sep 18, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 17, 2026 |
| BTIG | Buy | Buy | Maintain | Aug 3, 2026 |
| Goldman Sachs | Hold | Hold | Maintain | Jul 31, 2026 |
| Keybanc | Overweight | Sector Weight | Upgrade | Jul 23, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 22, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 16, 2026 |
| B of A Securities | Hold | Hold | Maintain | Jul 13, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 9, 2026 |
| Argus Research | Buy | Buy | Maintain | Mar 23, 2026 |
| UBS | Buy | Buy | Maintain | Feb 20, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 13, 2026 |
| Evercore ISI Group | Outperform | In Line | Upgrade | Jan 21, 2025 |
| Guggenheim | Neutral | Neutral | Maintain | Jul 7, 2023 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Oct 16, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Sep 17, 2019 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Sep 12, 2019 |
| Argus | Hold | Buy | Downgrade | May 5, 2018 |
| Wunderlich Securities | Hold | Hold | Maintain | May 3, 2013 |
| Wunderlich | Hold | Hold | Maintain | May 3, 2013 |
| Edward Jones | Hold | Sell | Upgrade | Dec 24, 2012 |
| Bank oferica | Underperform | Underperform | Maintain | May 8, 2012 |
| ISI Group | Hold | Hold | Maintain | Apr 12, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $99.64. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Anthony Crowdel | $113 | $100.25 | +13.4% | Sep 30, 2026 |
| Scotiabank | Ian Rapp | $104 | $99.39 | +4.4% | Sep 29, 2026 |
| RBC Capital | Stephen D\'Ambrisi | $107 | $98.46 | +7.4% | Sep 25, 2026 |
| Truist Financial | Analyst unavailable | $120 | $109.74 | +20.4% | Aug 17, 2026 |
| Mizuho Securities | Analyst unavailable | $124 | $109.61 | +24.4% | Aug 3, 2026 |
| BTIG | Analyst unavailable | $126 | $112.01 | +26.5% | Jul 23, 2026 |
| KeyBanc | Analyst unavailable | $122 | $112.01 | +22.4% | Jul 23, 2026 |
| Morgan Stanley | Analyst unavailable | $118 | $111.36 | +18.4% | Jul 22, 2026 |
| Barclays | Nicholas Campanella | $117 | $112.54 | +17.4% | Jul 9, 2026 |
| Morgan Stanley | David Arcaro | $115 | $112.71 | +15.4% | Jun 24, 2026 |
| Morgan Stanley | Analyst unavailable | $110 | $109.74 | +10.4% | May 21, 2026 |
| Morgan Stanley | David Arcaro | $117 | $110.68 | +17.4% | Apr 21, 2026 |
| Wells Fargo | Shahriar Pourreza | $120 | $111.27 | +20.4% | Apr 21, 2026 |
| Truist Financial | Richard Sunderland | $126 | $111.27 | +26.5% | Apr 20, 2026 |
| Barclays | Analyst unavailable | $116 | $111.86 | +16.4% | Apr 15, 2026 |
| BTIG | Alex Kania | $131 | $114.32 | +31.5% | Apr 9, 2026 |
| Morgan Stanley | David Arcaro | $116 | $109.46 | +16.4% | Feb 20, 2026 |
| UBS | William Appicelli | $127 | $109.31 | +27.5% | Feb 20, 2026 |
| Wells Fargo | Analyst unavailable | $113 | $109.4 | +13.4% | Feb 13, 2026 |
| Mizuho Securities | Analyst unavailable | $117 | $109.34 | +17.4% | Feb 13, 2026 |
| BMO Capital | Analyst unavailable | $120 | $109.34 | +20.4% | Feb 13, 2026 |
| RBC Capital | Stephen D'Ambrisi | $116 | $101.85 | +16.4% | Jan 23, 2026 |
| Morgan Stanley | David Arcaro | $108 | $103.75 | +8.4% | Jan 21, 2026 |
| Wells Fargo | Analyst unavailable | $111 | $104 | +11.4% | Jan 20, 2026 |
| Barclays | Nicholas Campanella | $104 | $102.54 | +4.4% | Jan 15, 2026 |
| UBS | Analyst unavailable | $115 | $97.99 | +15.4% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $103 | $98.87 | +3.4% | Dec 16, 2025 |
| Wells Fargo | Analyst unavailable | $112 | $104.81 | +12.4% | Oct 27, 2025 |
| RBC Capital | Stephen D'Ambrisi | $119 | $104.81 | +19.4% | Oct 27, 2025 |
| Mizuho Securities | Analyst unavailable | $114 | $104.18 | +14.4% | Oct 27, 2025 |
| Morgan Stanley | Analyst unavailable | $111 | $105.38 | +11.4% | Oct 22, 2025 |
| Barclays | Analyst unavailable | $111 | $104.92 | +11.4% | Oct 21, 2025 |
| Barclays | Analyst unavailable | $113 | $105.69 | +13.4% | Oct 21, 2025 |
| KeyBanc | Analyst unavailable | $109 | $104.23 | +9.4% | Oct 15, 2025 |
| Morgan Stanley | David Arcaro | $104 | $101.13 | +4.4% | Sep 25, 2025 |
| KeyBanc | Sophie Karp | $104 | $96.46 | +4.4% | Jul 16, 2025 |
| UBS | William Appicelli | $114 | $96.2 | +14.4% | Jul 11, 2025 |
| Goldman Sachs | Carly Davenport | $100 | $95.1 | +0.4% | Jun 25, 2025 |
| Morgan Stanley | David Arcaro | $102 | $95.4 | +2.4% | May 22, 2025 |
| KeyBanc | Sophie Karp | $103 | $95.42 | +3.4% | May 14, 2025 |
| Barclays | Analyst unavailable | $102 | $100 | +2.4% | Mar 4, 2025 |
| Jefferies | Julien Dumoulin-Smith | $97 | $83.62 | -2.6% | Sep 19, 2024 |
| Mizuho Securities | Anthony Crowdel | $89 | $83.99 | -10.7% | Sep 16, 2024 |
| BMO Capital | James Thalacker | $87 | $80.85 | -12.7% | Aug 6, 2024 |
| UBS | Daniel Ford | $87 | $74.82 | -12.7% | Jul 19, 2024 |
| BMO Capital | James Thalacker | $80 | $71.13 | -19.7% | Jun 21, 2024 |
| Barclays | Nicholas Campanella | $77 | $70.1 | -22.7% | May 30, 2024 |
| Goldman Sachs | Carly Davenport | $73 | $74.9 | -26.7% | May 16, 2024 |
| BMO Capital | James Thalacker | $81 | $73.85 | -18.7% | May 6, 2024 |
| Wells Fargo | Neil Kalton | $94 | $78.55 | -5.7% | Oct 19, 2023 |
| Barclays | Eric Beaumont | $80 | $77.43 | -19.7% | Sep 5, 2023 |
| KeyBanc | Sophie Karp | $90 | $83.36 | -9.7% | Jun 11, 2023 |
| Morgan Stanley | Analyst unavailable | $92 | $88.16 | -7.7% | Dec 15, 2022 |
| Morgan Stanley | Analyst unavailable | $86 | $84.86 | -13.7% | Nov 11, 2022 |
| Mizuho Securities | Anthony Crowdell | $92 | $88.24 | -7.7% | Jul 8, 2022 |
| Argus Research | Analyst unavailable | $102 | $93.73 | +2.4% | Jun 3, 2022 |
| Argus Research | Analyst unavailable | $112 | $96.36 | +12.4% | May 26, 2022 |
| Mizuho Securities | Analyst unavailable | $98 | $95.8 | -1.6% | Apr 26, 2022 |
| Credit Suisse | Analyst unavailable | $104 | $95.92 | +4.4% | Apr 26, 2022 |
| Morgan Stanley | Analyst unavailable | $101 | $97.75 | +1.4% | Apr 20, 2022 |
| Argus Research | Gary Hovis | $90 | $79.7 | -9.7% | Jun 24, 2021 |
| Bank of America Securities | Julien Dumoulin Smith | $89 | $81.8 | -10.7% | Jun 21, 2021 |
| Goldman Sachs | Insoo Kim | $90 | $84.49 | -9.7% | Jun 15, 2021 |
Track every rating change on AEE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationOperating across the United States, Ameren Corporation functions as a utility holding company. The enterprise organizes its operations into four primary divisions: Ameren Missouri, Ameren Illinois Electric Distribution, Ameren Illinois Natural Gas, and Ameren Transmission. Its fundamental business involves the rate-regulated production, transmission, and supply of electricity, in addition to the rate-regulated distribution and transmission of natural gas. Ameren generates power using a variety of sources, including coal, nuclear energy, and natural gas, supplemented by renewable alternatives such as hydroelectric, wind, methane gas, and solar. Its customer base encompasses residential homes, commercial businesses, and industrial operations. Established in 1881, Ameren Corporation is headquartered in St. Louis, Missouri.
Historical context
All AEE earningsLatest beats and misses
Who reports nextBeat on EPS
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
- MUFY2026 Q4 · September 30, 2026+5.4% EPS+0.0% move
- CCLFY2026 Q3 · September 29, 2026+5.9% EPS+13.4% move
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
Get the AEE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:22.444131+00:00
- Polygon adjusted daily market bars · 2026-10-02T04:26:06.357128+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-02T04:26:06.354055+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-02. For educational purposes only; not investment advice.